SCOTUS mulls limiting class actions in Amgen case
This article was originally published in Scrip
Executive Summary
The question of what Amgen knew about the FDA's safety concerns for the company's erythropoiesis-stimulating agents (ESAs) Aranesp (darbepoetin alfa) and Epogen (epoetin alfa) and when the firm shared that information with investors is at the heart of a lawsuit that could determine whether plaintiffs must prove harm before bringing securities class action cases in the US – with the nation's highest court hearing oral arguments in the case on 5 November.